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ABSTRACT 
 
 Type-1 diabetes (T1D), also known as insulin-dependent diabetes, is 
characterized by the inability of pancreas to produce sufficient amount of insulin to 
regulate blood glucose level in the body. Long-term complications such as nephropathy, 
neuropathy, retinopathy and cardiovascular disease make T1D a major health problem 
throughout the world. For the past few decades, allotransplantation of insulin-producing 
islets from the pancreas of deceased human donors has shown promising results in the 
restoration and sustenance of normoglycemia. Islet transplantation is a suitable procedure, 
especially for adolescents since it has substantially lower risk in operating procedure than 
whole-pancreas transplantation. However, only small percentage of patients of T1D can 
be treated with islet allotransplantation because of the limited donor availability. 
 Xenotransplantation using porcine islet is a good alternative treatment of T1D. 
Porcine islet is an ideal substitute of beta cell function for human islet for several reasons: 
availability, compatibility and functional similarity to human islets. In recent years, 
treatment with porcine islets has shown significant progress of providing sustained 
normoglycemia in diabetes-induced nonhuman primates (NHPs), which has demonstrated 
the feasibility of clinical xenotransplantation. Yet, there are still a number of barriers to 
overcome in order to accomplish successful clinical application for xenotransplantation. 
 Harvesting and preserving viable islets with high yield is a first crucial step in 
porcine islet xenotransplantation. The major limiting factor, however, is the intrinsic 
fragility of the porcine pancreas that causes various complications in obtaining sufficient 
amount of healthy islets. Early inflammatory responses and rejection are also the major 
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problems for clinical xenotransplantation. Immunosuppressive drug is used to regulate 
the inflammation yet the drug itself in long term induces toxicity in the body. Securing 
the islets with appropriate encapsulation technology is crucial as it ensures the prolonged 
viability and function of the islets while avoiding immune reaction from the host after the 
transplant. 
 In the first part of the thesis, we demonstrate the isolation and purification method 
composed of three key components: enzymatic digestion, mechanical disruption and 
density gradient purification. Porcine pancreata were procured from young commercial 
breed pigs from the university slaughterhouse. Average time consumption of single islet 
isolation with the modified procedure is 60 min. Islet yield, purity, viability, in vitro 
function, and morphology were assessed after the isolation. The resulting islet viability 
and purity were comparable with those achieved in published literature. Clinically 
relevant yield and quality can be obtained with the use of standard laboratory equipment, 
which makes this method time- and cost-effective. 
 The second part of the thesis presents single-step fabrication of core/shell alginate 
microcapsules using precision particle fabrication (PPF) system to demonstrate the 
feasibility of successful clinical xenotransplantation. PPF system has following 
capabilities: precise control of capsule size, ability to process material with high viscosity, 
high throughput and prevention of cell protrusion. These advantages allow only minimal 
intervention during the fabrication process, thus making the system suitable for various 
cell delivery applications including islet encapsulation. Islets with appropriate 
concentration (in IEQ) for clinical applications were encapsulated in the core of the 
microcapsules with PPF system. The average duration of microcapsule fabrication 
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process was 10 min.  Islet morphology and viability were assessed immediately after the 
encapsulation. The intracapsular environment of the alginate microcapsules induces cell-
cell and cell-matrix interactions, thus providing hospitable environment for the 
encapsulated islets. The results showed islets with high survivability after the entire 
encapsulation process. Future study aimed for improved viability and function of the 
islets in vivo can further support the rationale of the present method as alternative 
therapeutic option for T1D patients. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background 
The International Diabetes Federation (IDF) stated diabetes as one of the largest 
global health emergencies of the 21st century.  As of 2015, there are 415 million people 
suffering from diabetes worldwide and the number will be increased up to 642 million by 
year 2040 (http://www.diabetesatlas.org). Type 1 diabetes (T1D) accounts for 10% of 
these cases. Progressive immune destruction of insulin-producing beta cells is the major 
indication of T1D which causes various secondary complications such as nephropathy, 
neuropathy and retinopathy [1]. Insulin injection is a common method of treatment for 
T1D; however, the process is cumbersome, as it requires constant daily insulin injections, 
dietary restrictions and monitoring of blood glucose level of the patients. Furthermore, it 
is difficult to use insulin therapy to permanently maintain blood glucose level within 
physiological range. Since the fundamental reason for T1D is the loss of functional beta 
cells in pancreas, a cure for patients with T1D involves the use of replacement islets 
containing beta cells with the ability of sensing blood glucose level and secreting 
appropriate amount of insulin [2, 3].  
Pancreas allotransplantation and islet allotransplantation are currently the most 
effective and reproducible therapies to achieve normoglycemia [4-7]. The goals of the 
allotransplantation are to reestablish long-term glucose-regulated insulin secretion, 
alleviate the progression of secondary complications of T1D, and improve quality of life 
[8]. Experimental human islet transplantation has been shown to be effective in reversing 
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hyperglycemia in rodents, canines [9] and primates [10]. Ever since the first successful 
whole pancreas allotransplantation to T1D patients in 1966 [11], there has been many 
experimental clinical trials conducted using deceased organ donors. Pancreas 
allotransplantation is now widely accepted as therapeutic modality for T1D [12, 13]. 
However, only selective number of transplantations can be performed due to the limited 
supply of human donors. Average of 1,200 cases are performed annually in the United 
States [14]. Difficult surgical procedures and complications after transplantation such as 
graft thrombosis, pancreatitis, pancreatic fistulae and pseudocyst formation are also the 
major disadvantages of whole pancreas transplantation [15].  
Pancreatic islet transplantation has substantially low risks compare to whole 
pancreas transplantation, which makes it more accessible to patients with all age groups, 
especially for adolescents [16, 17]. The procedure involves the selective transplant of 
islets, isolated from the pancreas of the donors, into the portal vein of the liver, therefore 
less invasive and has minimal or no complications after transplant [18]. First successful 
clinical trial was held in 2000 by Shapiro, et al., [19] with the use of the Edmonton 
Protocol where all seven patients quickly attained insulin independence after 
transplantation and sustained for medium duration of 11.9 months. Since then, islet 
transplantation with the use of the Edmonton Protocol has expanded worldwide as a well-
established proof-of-concept for T1D treatment [20-22]. Despite the cases of long-term 
success and rapid progression, however, there are two major barriers that hinder the 
overall efficiency and effectiveness of islet allotransplantation in clinical application.  
 The first limiting factor is donor availability. At least two cadaveric pancreas 
donors are typically required for one islet transplantation which leads to the problem of 
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mismatch between donor supply and patient demand. There has been search for 
alternative source of islets which can compensate for the high demand as well as match 
the criteria for clinical trials. Porcine islet is currently viewed as an ideal substitute to 
human islet for following reasons: (1) availability; (2) physiological compatibility 
between porcine insulin and human insulin; (3) possibility of genetic modifications for 
improved compatibility for clinical applications and (4) ethical regulation conditions [23-
25]. Tissues from pigs are proven to be safe and have been used in several clinical 
applications. Porcine insulin, with only one amino acid difference to human insulin, 
already has been widely utilized in the treatment of T1D [26]. 
The second limiting factor is immune-related complications. Islets from an 
exogenous source, such as porcine islets, are heterologous to human recipients. Although 
islet xenotransplantation has been utilized in many clinical studies, the recipients had to 
take immunosuppressing agents to prevent graft rejection and maintain long-term 
normoglycemia without graft loss. Chronic immunosuppressive therapies can be toxic to 
the transplanted islets and to other organs of the recipients [27-29].  Immunoisolation 
using encapsulation technology is a strategy in which islets can be protected from host’s 
immune system after the transplant without immunosuppressive therapy. The strategy 
involves entrapment of islets in a biocompatible micro-barrier with selective-permeable 
membrane which can protect islets from early or chronic immune responses, while 
allowing influx of oxygen, nutrients and ,most importantly, outflow of insulin secreted 
from entrapped islets [30]. Several studies demonstrated the effectiveness of 
microencapsulation of porcine islets using various biocompatible materials such as 
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alginate and agarose gels to reverse diabetes in rodents, canines and non-human primates 
with the absence of immunosuppressive agents [31-34].   
Cell viability and function should be maintained during the encapsulation process. 
Furthermore, high throughput should be allowed to shorten the intervening period 
between hospitalization and transplantation. 
 
1.2. Objectives and Contributions 
The aim of this study is to demonstrate the porcine islet isolation and purification 
using modified Ricordi method involving collagenase digestion and Ficoll density 
gradient purification in order to obtain porcine islets with high yield and high purity. 
Furthermore, this study provides the feasibility of using precision particle fabrication 
(PPF) system for clinical xenotransplantation of encapsulated porcine islets using single-
step fabrication of core/shell alginate microcapsules. 
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CHAPTER 2 
ISOLATION AND PURIFICATION OF PORCINE ISLETS 
 
2.1. Literature Review 
This chapter reviews the current progress of porcine islet isolation and purification 
methods to emphasize the significance of the three steps: collagenase digestion, 
mechanical disruption and Ficoll density gradient purification.  
 
2.1.1. Porcine Islet Isolation & Purification 
 Xenotransplantation using pig as main islet source is currently the most favorable 
alternative to islet allotransplantation in T1D treatment for following reasons: (1) 
unlimited supply of islet source; (2) anatomic and physiological similarity of porcine 
pancreas with human pancreas and (3) advanced progress for possible clinical 
applications [28, 35, 36]. There are many experimental studies that demonstrated the 
feasibility of using porcine islets in clinical applications by showing success in restoring 
normoglycemia of diabetes induced non-human primates for over 6 months [10, 21, 31, 
37, 38]. However, the fragility of porcine pancreas makes the overall isolation and 
purification procedure difficult and inconsistent in outcome [39, 40]. 
 Obtaining healthy islets with high yield is the first crucial step for porcine islet 
xenotransplantation. These are the following factors affecting the quality and quantity of 
isolation and purification outcome: (1) physical characteristics of donor pigs; (2) 
procurement environment and (3) isolation and purification techniques [41].   
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2.1.1.1. Physical Characteristics 
 Physical characteristics of donor pigs include age, sex, and strain. One has to 
consider the optimum condition for each physical aspect in order to secure porcine islets 
with high yield and function for clinical xenotransplantation. 
 Numerous studies have shown the differences in xenotransplantation outcome of 
fetal, neonatal, and adult porcine pancreata. Although there have been reports about 
feasibility of achieving normoglycemia in non-human primate models in fetal, neonatal 
and adult porcine islets, there is no conclusive evidence to decide which age of porcine 
islet source is optimal with regard to porcine islet xenotransplantation [10, 21, 30, 42].  
 In the early embryonic to neonatal stage of development, which is up to 30 days 
after birth, insulin-positive cells start to form into islet-like cell clusters (ICC) [43]. The 
majority of the ICCs consists of epithelial precursor cells, with the absence of definite 
connective tissues or vasculature, and only less than 40% of the cell clusters are 
differentiated into endocrine cells including insulin-producing beta cells [44]. Since 
pancreas has no rigid structural matrix to protect the cluster of insulin-positive cells, the 
isolation procedure for fetal and neonatal pancreata is known to be simple as it does not 
require thorough enzymatic digestion and purification process [45, 46]. However, the 
average yield of ICCs is reported to be lower than the islet yield from adult pancreata and 
it requires 5-7 days of tissue culture for selective survival and maturation of ICCs into 
glucose-responsive islet cells [47].  
 Pig donors with the age above 6 months are categorized as adult pigs.  Matured 
porcine pancreata contains islets with rigid structural matrix and definite connective 
tissues and vasculature. The average islet yield from adult pigs is significantly higher 
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than from neonatal or fetal pigs [40, 48, 49]. Immediate graft function against 
hyperglycemia after transplantation is also one of the major advantages of using adult 
porcine islets.  According to the previous studies, sufficient amount of functional islets 
can be procured from a single adult porcine pancreas to perform one or two 
xenotransplantation to non-human primates [50]. Despite high yield and immediate 
functionality, there are some disadvantages of using adult porcine pancreas such as 
sensitive immunogenicity, difficult isolation procedure, cost and inconsistent isolation 
outcomes [39, 51-53]. Nevertheless, adult pig has been recognized as the major donor 
source for clinical islet xenotransplantation.  
 There is no definitive result showing which sex/gender is better in terms of the 
quality of islet isolation outcome. Some studies favored retired female breeders as the 
isolation results showed procurement of islets with high yield and good compact 
morphology [40, 48, 49], while other studies suggested using uncastrated male adult pigs 
with favorable isolation yield [41].  
 Several studies have reported that choosing the right breed or strain of pigs, 
especially for young and adult pigs, have significant impact on the yield of islet isolation 
[54-56]. Study by Kirchhof et al. [57] showed that German Large White (GLW) and 
German Landrace (GL) have pancreas with more islets per area than Pietrain (PI), Duroc 
(DU), and Hampshire (HA). Ulrichs et al. [58] reported that GL has relatively higher islet 
volume density (percent endocrine tissue of the total pancreas mass) than PI, DU, hybrid, 
and wild breeds. In contrast, the study by Heiser et al. [59] showed higher islet yield with 
PI compared with GL or hybrid pigs. Kim et al. [23, 41] recently achieved very high islet 
yield with specific-pathogen-free (SPF) Chicago Medical School (CMS) miniature pigs 
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(now renamed to Seoul National University miniature pigs) which was not achievable by 
using miniature pigs with different strains [60]. Since the variability of isolation 
outcomes was considerably high among isolation attempts from different research groups, 
there is no best option in terms of choosing breed of donor pigs.  
 
2.1.1.2. Procurement environment 
 In order to secure viable and functional islets while minimizing risk of 
transmission of infectious agents, it is important to consider the procurement environment 
[23, 61]. In many previous studies, procurement procedures were conducted at 
slaughterhouses. Several problems such as non-sterile surgical environment, less control 
in breeding conditions of donor pigs, and most importantly, exposure of pancreas to long 
warm ischemic time (WIT) and cold ischemic time (CIT) led to inconsistencies in 
isolation outcome.  [62-64]. It is crucial to minimize WIT and CIT during pancreas 
procurement in order to prevent inflammation and cell apoptosis, therefore improving the 
survivability of islets after isolation and purification stage [65, 66]. Successful porcine 
islet xenotransplantation to non-human primate models were achieved with WIT within 
10 min [51].  
 
2.1.1.3. Isolation and purification technique 
 The islet yield and viability can be drastically changed under different isolation 
and purification techniques [67]. After the establishment of Edmonton protocol [19] and 
automated continuous digestion filtration [68], there has been increased number of 
clinical islet transplantation due to the improved islet yield and purity. The procedure 
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involves three major steps: (1) enzymatic pancreatic digestion; (2) mechanical pancreatic 
disruption; and (3) purification of isolated islets [47, 69].  
 Islets of Langerhans are highly vascularized and widely distributed inside the 
pancreas. The primary objective of enzymatic pancreatic digestion is to liberate the islets 
from the surrounding acinar tissues. Collagen is one of the essential components of the 
extracellular matrix of the pancreas which can be only degraded by selective protease 
activities [70]. Intraductal injection of collagenase, an enzyme that breaks the peptide 
bond of collagen, into the pancreatic duct of pancreas had naturally become the standard 
strategy for enzymatic digestion [71, 72]. Collagenase not only dissociates the exocrine 
tissues of the pancreas but also affects the islets; therefore, it is important to consider 
various factors such as different types of enzyme blends, the concentration of the enzyme, 
and the duration of the digestion in order to optimize the isolation outcome after the 
enzymatic digestion stage [55, 73, 74]. Many studies have used mixture of highly pure 
collagenase with neutral proteases and clostripains to stabilize the digestion while 
effectively dissociate the exocrine tissues within short amount of time [75].  
 Once enough collagenase is distributed to the internal matrix, the pancreas is then 
cut into several small pieces and transferred to a digestion chamber for mechanical 
disruption, which is a process of physically increasing the area of enzymatic digestion, 
therefore enhancing the dissociation of the pancreatic acinar tissues. Well established 
methods include agitating the digestion chamber either manually [71, 76] or 
automatically [68] for improved separation of the islets from surrounding acinar tissues. 
The islet separation (cleave index) was more effective with the automated method; 
however the overall procedure and installation are complicated and expansive. Although 
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manual method has relatively low cleave index, the procedure is much cheaper and easy 
to handle [77, 78]. 
 The purification step involves extraction of isolated islets from the digestion 
chamber and removal of pancreatic tissue fragments. Good experience in different 
purification techniques determines the purity and recover rate of islets after the isolation. 
Discontinuous density gradient is recognized as the standard method for the islet 
purification; however the purification outcome has not been consistent amongst the 
previous studies because the outcome is subjective to one’s technique and experience 
along with ambiguity in assessment [79]. Islet purity from the early studies was less than 
40%, which could be explained by the low experience in isolation and purification 
method in the initial stage of development [79, 80]. More recent studies showed drastic 
improvement in islet purity as high as 75-95% by substituting different types of gradient 
solvent or implementing chemical-free filtration methods [41, 81, 82]. 
 The studies by Mirkovitch et al. [83] and Kretschmer et al. [84] demonstrated the 
significance of islet purification with canine models by experimenting autotransplantation 
without the purification step. The pancreatic tissue fragments and toxic subcellular 
particles induced host’s immune response, which eventually led to several post-transplant 
complications such as malnutrition and total pancreatectomy. 
 
2.2. Materials and Methods 
2.2.1. Porcine pancreas procurement 
 4-6 months old Duroc-Yorkshire hybrid pigs from University of Illinois Meat 
Science Laboratory slaughterhouse were used for this experiment. Two porcine pancreata 
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were procured, immersed in 4°C Hank’s balanced salt solution (HBSS) with 10% FBS 
and transported to the laboratory. The warm ischemia time (WIT) was 10 min and the 
cold ischemia time (CIT) was minimized to 30 min. Before initiating the isolation 
procedure, fat tissues and blood vessels on the surface of the pancreas were trimmed with 
surgical scissors.  
 
2.2.2. Porcine pancreas isolation  
 Modified Ricordi method [47] was used to perform islet isolation. In order to use 
only the splenic lobe, the duodenum lobe and connective lobe of the donor pancreas were 
removed with surgical scissors. The pancreatic duct of the splenic lobe was located and 
cannulated to slowly infuse 200 mL of collagenase solution (1 mg/mL collagenase from 
Clostridium histolyticum in HBSS with 10% FBS, Sigma, St. Louis, MO). After the 
infusion, the splenic lobe was cut into small pieces and incubated in a shaking incubator 
at 37°C for 15 min for further enzymatic digestion. 100 mL of 4°C HBSS with 10% FBS 
was added to the digested tissues to dilute the collagenase solution in order to prevent 
collagenase from damaging the isolated islets. Stack of three sterile meshes with the 
diameters of 1.18, 0.71 and 0.595 mm were used to filter the digested tissues. The filtrate 
containing isolated islets were transferred to 50 mL conical tubes and centrifuged at 
1,500 rpm for 2 min at 4°C to remove collagenase. 
 
2.2.3. Porcine pancreas purification  
 The isolated islets were gently resuspended in 6 mL of 25% (w/v) Ficoll solution 
in dH2O (Ficoll 400, Sigma, St. Louis, MO). A discontinuous gradient of 23, 20.5 and 11% 
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(w/v) Ficoll solutions were slowly layered, respectively, on top of the islet suspension 
and centrifuged at 2,500 rpm for 10 min at 4°C. The top Ficoll layer, where the majority 
of the islets congregated after centrifugation was collected to a new 50 mL conical tube. 
Centrifugation, at 2,500 rpm for 10 min, was used to discard Ficoll solution and wash 
islets two times with HBSS. The purified islets were resuspended in RPMI-1640 with 10% 
FBS and 1% Pen/Strep and incubated in water-jacketed CO2 incubator at 37°C with 5% 
CO2. 
 
2.2.4. Islet evaluation   
 Dithizone (DTZ) staining [85, 86] was used to determine the quantity and quality 
of the isolated porcine islets. 100 ul of DTZ stock solution (5 mg/ml in DMSO) was 
added to 1 ml aliquot of islet sample in a calibration grid. After letting DTZ to stain the 
insulin granules of the islets, red color stained islets were identified and counted using 
optical microscope. The total quantity (islet particle number, IPN) of the islets was 
converted to islet equivalents (IEQ) for standardized assessment of islet quantity.  
 Trypan blue staining [87] and SYTO-green/Ethidium bromide (EB) staining [88, 
89] were used, respectively, to quantitatively and qualitatively assess islet viability 
immediately after the purification. 100 ul of 0.4% trypan blue solution in PBS was added 
to 1 ml aliquot of islet sample in a calibration grid. Optical microscope was used to 
quantify the viable cells as a means to assess viability of islets after isolation and 
purification. In a separate calibration grid with 1 ml aliquot of islet sample, 100 ul of 
SYTO-green solution (5mM in DMSO) and 50 ul of EB (10 mg/ml) were added 
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consecutively. Fluorescence microscope was used to separately identify viable and dead 
islet cells.   
 In vitro function of the islets was assessed by measuring their dynamic insulin 
secretory response under low or high glucose stimulation [90]. One group (n=4) of islets 
was challenged with low glucose stimulation (1.67 mM) while the other group (n=4) was 
challenged with high glucose stimulation (16.7 mM) for 60 min at 37°C with 5% CO2. 
Porcine Insulin ELISA assay kit (Mercodia, Uppsala, Sweden) was used to assess the 
resulting responses.  
 
2.2.5. Statistical analysis  
 All data were expressed as mean ± standard deviation (SD). Data comparisons 
were performed by one-way student t-test. Differences with p < 0.05 were considered 
statistically significant. 
 
2.3. Results and Discussion 
2.3.1. Islet yield and morphology  
 Total of two porcine pancreata of 4-6 months old Duroc-Yorkshire hybrid pigs 
were used for this experiment. Only the splenic lobe of each pancreas was used as it has 
shown more consistent isolation results compared to those using whole pancreas [91, 92]. 
Table 1 shows that two separate operations, with the average splenic lobe weight of 73.0 
± 0.57 g, gave similar islet isolation results with 2,460 ± 404 IEQ/g before the 
purification and 1,950 ± 526 IEQ/g after the purification which were similar to those 
reported with the same collagenase source [91]. The average recovery rate and viability 
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were 78.6 ± 8.49% and 88.9 ± 0.57%, respectively, which were also similar to those 
reported previously [60]. Figure 1 shows the morphology of the isolated porcine islets 
before and after DTZ staining. The isolated islets had round or oval shape with distinct 
golden brown color. Rigid surface structure without any cell protrusion indicates the 
healthy condition of isolated islets [93]. The size of the islets were varied from 50 um to 
250 um which is shown in Figure 2. Enzyme source and Enzymatic digestion duration are 
reported to be important factors for determining the size distribution and yield of isolated 
islets [94]. With the procedure presented in this study using crude collagenase, with the 
exposure time of 20 min, showed the majority of islets (80%) distributed within 50-150 
um size range. Large diameter islets (>100 um) with more centralized vascular structure 
can endure against the damage from the enzymatic digestion and thus have a potential for 
better viability and function after isolation and purification [53]. However, islets with 
larger diameter (>150 um) and concentrated core are reported to be more susceptible to 
hypoxia compared to small size islets because of the difficulty of oxygen supply to the 
core of the islet clusters [95]. Hypoxia-induced apoptosis causes decrease in islet viability 
and impairs beta cell function [96, 97]. Bright red color from DTZ staining represents the 
insulin-containing beta cells inside the islet clusters [85]. Figure 3 visually depicts the 
viability of the isolated and purified porcine islets. Group of Islets with average viability 
above 70% is considered to be viable sample [98].  
 
2.3.2. Islet function in vitro  
 Table 2 shows the average glucose-stimulated response of the isolated porcine 
islets immediately after purification. The isolated islets had average insulin secretion of 
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3.29 ± 1.51 μU/IEQ/hr at low glucose stimulation (1.67 mM) and 5.88 ± 1.27 μU/IEQ/hr 
at high glucose stimulation (16.7 mM). The stimulation index (SI), which is a ratio 
between insulin secretion at high and low glucose stimulation, is a widely used parameter 
to determine the level of function of isolated islets [99]. The resulting SI for this 
experiment was 2.01 ± 0.72 which was within the range from the previous studies which 
was from as low as 1.5 to as high as 2.58 [99, 100].  
 
2.4. Conclusion 
  In this study, we demonstrated a modified isolation procedure using crude 
collagenase and purification using Ficoll discontinuous density gradient method [101]. 
The average yield after purification was 1,950 ± 526 IEQ/g after the purification with the 
viability of 88.9 ± 0.57%. Establishing a laboratory with an isolation method to preserve 
viable islets with high yield is a first crucial step for the future work regarding islet 
xenotransplantation. Isolated and purified islets from two porcine pancreata were 
sufficient in amount to be used for the microencapsulation using precision particle 
fabrication (PPF) method.  
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2.5. Tables and Figures 
Table 1. IPN, IEQ, recovery and viability assessment 
  Splenic lobe weight (g) 
 
 Pre-Purification 
  
 Post-Purification  Recovery (%)* 
 Viability (%)  IPN 
  
 IEQ  IEQ/g  IPN  IEQ  IEQ/g 
 Median   73.0 
 
 314,000  179,470  2,460  176,800  142,214  1,950  78.6  88.9 
SD 
 
0.57 53,740 28,106 404 10,182 37,347 526 8.49 0.57 
IPN: islet particle number   IEQ: islet equivalents   * Recovery (%) = IEQ (pre-purification) / IEQ (post-purification) x 100   
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Table 2. Glucose-stimulated insulin secretion (GSIS) 
 IEQ/g (post-purification) 
 GSIS (μU/IEQ/hr) 
 
 Stimulation index (SI)* 
 
Low glucose  High glucose 
 
 1,950±526 
 
 3.29 ± 1.51 
 
 5.88 ± 1.27 
 
 2.01 ± 0.72 
 Stimulation index = high glucose GSIS / low glucose GSIS  
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 Figure 1. Morphological characteristics before (left) and after (right) dithizone (DTZ) staining of isolated porcine islets. DTZ (red) selectively stains pancreatic beta cells by chelating the zinc ions presented in the insulin granules of the islets. Scale bar = 200 μm.   
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 Figure 2. Average size distribution of isolated islets from two porcine pancreata. Data are represented as mean ± SD (n=2).   
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 Figure 3. Optical (left) and fluorescence (right) micrographs of isolated porcine islets. SYTO-green staining and ethidium bromide (EB) staining were used to visualize islet viability after isolation and purification. SYTO-green (green) stains viable islets and EB (red) stains dead islets.  Scale bar = 500 μm (top) and 200 μm (bottom).                 
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CHAPTER 3 
PORCINE ISLET ENCAPSULATION USING  
PRECISION PARTICLE FABRICATION (PPF) METHOD 
 
3.1. Literature Review 
This chapter explains the fundamental concept of applying precision particle 
fabrication (PPF) system into various cell delivery applications, especially for clinical 
xenotransplantation of porcine islets for T1D treatment. 
 
3.1.1. Immunoisolation 
 The rapid progression in the field of islet isolation and purification solidifies the 
feasibility of clinical islet xenotransplantation; however, achieving long-term success of 
insulin independence in clinical trials still remains uncertain. Pancreatic islets from 
xenogeneic source, such as porcine islets, are subject to human recipient’s immune 
reaction, which eventually leads to graft rejection. Most studies demonstrated that CD4+ 
T cells mainly trigger acute xenograft rejection [102, 103]. Direct contact of transplanted 
porcine islets with the host’s blood triggers instant blood-mediated inflammatory reaction 
(IBMIR) which causes many complications such as coagulation, islet-membrane leakage 
and antibody deposition [104, 105]. Therefore, the current clinical therapy requires the 
use of anti-rejection medication, also known as immunosuppressive medication, to 
achieve chronic immunosuppression which is to protect transplanted islet grafts from 
host’s immune reactions. However, the prolonged exposure to even the most optimized 
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medications is known to be toxic to both transplanted islets and recipient’s own organs 
[28, 106].  
 One approach to prevent post-transplant rejection is to use immunoisolation 
strategy of encapsulating islets with immuno-protective biomaterial [107]. The semi-
permeable membrane formed by the biomaterial serves as an immuno-barrier that 
protects the encapsulated islets from the host’s immune system, thereby allowing islets to 
regulate blood glucose level for a longer period of time [108, 109]. 
  
3.1.2. Microencapsulation 
 Ever since the first implementation, which is now categorized as first-generation 
drug delivery system, in 1952 by the pharmaceutical company Smith Kline & French 
[110], the concept of controlled-release drug delivery system has been widely studied and 
utilized in various drug and live cell based treatment. The first-generation (1950-1980) 
was mainly focused on establishing sustained release therapy by controlling the release 
kinetics of the injected drug. The mechanism is based on drug’s behavior to dissolution, 
diffusion, osmosis and ion exchange [111]. The first-generation delivery methods are still 
commonly used for producing ‘once or twice a day’ delivery system. Despite the success 
of the first-generation delivery system, there has been an increasing attempt of 
developing more advanced delivery system to achieve higher efficiency and safety, which 
naturally led to the beginning of the era of second-generation delivery system (1980-
2010). The development of micro- and nanotechnology has triggered the development of 
various drug encapsulation strategies using smart polymers and hydrogels [111, 112]. 
Micro- and nano-encapsulation with attractive properties showed the following 
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advantages in the field of drug delivery system: (1) an effective protection of the 
encapsulated agents from damage from enzymatic degradation or immune reaction; (2) 
more accurate controllability in drug release kinetics based on environmental factors; and 
(3) easy administration with less dosage frequency [113]. Microcapsules, or microbeads, 
can serve as reservoir of all sorts of substances in solid or liquid form and are, therefore, 
suitable for delivering various active agents such as drugs, proteins, bacterial cells and 
stem cells. The well-defined barrier formed by the microcapsules can safely protect the 
encapsulated agents from host’s immune reactions, thus allowing more controlled and 
sustained release [114, 115]. Number of studies has shown the immunoprotection 
capability of microcapsules in Parkinson’s, Alzheimer’s, and type 1 diabetes (T1D) [116-
119]. Additionally, the semipermeable membrane with porous surface of the 
microcapsules allows influx of essential molecules such as nutrients and oxygen to 
maintain cell survival, and efflux of therapeutic agents such as insulin to induce sustained 
treatment of the target disease [120, 121].  
 
3.1.3. Biomaterial: Alginate 
 Among the list of many biomaterials, alginate has emerged as one of the most 
extensively explored in drug delivery applications due to the following appealing 
characteristics: (1) good biocompatibility and cytocompatibility; (2) control in 
biodegradation; and (3) versatility in modifications [122, 123]. In addition, and most 
importantly, alginate dissolved in aqueous solution can be ionotropically crosslinked 
using divalent cations such as calcium (Ca2+), barium (Ba2+) and strontium (Sr2+), which 
instantly convert alginate solution into 3D matrix called hydrogel. Fast crosslinking is 
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one of the strongest suits that make alginate the most suitable biomaterial to be used in 
encapsulation of sensitive or delicate bio-agents such as proteins, genes and living cells 
[124-126]. 
 
3.1.4. Precision Particle Fabrication (PPF) System  
 There are many methods to prepare alginate microcapsules which can be divided 
into three categories: chemical, physiochemical, electrostatic and mechanical processes 
[113]. One needs to consider how to provide required amount of therapeutic agents at the 
given amount of time to the target location to optimize the efficacy and minimize side 
effects [127]. Precision particle fabrication (PPF) system pioneered by Kyekyoon (Kevin) 
Kim [128, 129], which uses acoustic excitation to mechanically generate uniform 
microdroplets from a liquid jet containing polymer solution, has the following appealing 
capabilities: (1) precise control of microcapsule size and uniformity; (2) handling of 
polymer solution with high viscosity; (3) prevention of protrusion of inner content by 
forming core/shell structure; and (4) high throughput and rapid process [127]. Alginate in 
aqueous solution is highly viscous, therefore difficult to handle with conventional 
fabrication method. However, PPF system with its acoustically excited pressure can 
break a liquid jet, consisting of alginate solution, into uniform microdroplets in desired 
size. The dual nozzle allows PPF system to generate microdroplets with core/shell 
structure in order to safely immobilize various cell sources, such as porcine islets, inside 
the microcapsules, thereby being able to achieve immunoisolation from host’s immune 
cells.  
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 As a novel cell encapsulation method, PPF system was used in this study to 
produce semi-permeable alginate core/shell microcapsules encapsulating porcine islets to 
further demonstrate the potential of islet transplantation in the treatment of T1D. 
 
3.2. Materials and Methods 
3.2.1. Islet encapsulation 
 Modified PPF method [130] was used to produce alginate microcapsules with 
spherical shape and uniformity. 2.0% (w/v) and 1.5% (w/v) alginate solutions were 
prepared by dissolving sodium alginate (Protanal® SF 120 alginate, FMC, Philadelphia, 
PA) in dH2O. The pH of the solution was set to 7.2 for biological use. Isolated islets, 
which went through overnight recovery at 37°C with 5% CO2, were collected from the 
cell medium (RPMI 1650 with 10% FBS and 1% PS) by centrifugation (3,000 rpm for 5 
min) and gently dispersed in 1.5% (w/v) alginate solution. 2.0% (w/v) alginate solution 
and 1.5% (w/v) alginate solution containing islets (8,000 islets/ml) were sent through the 
outer and inner tube of the dual coaxial nozzle, respectively, with two separate syringe 
pumps. The dual coaxial nozzle with applied flow rates of 2.3 and 4.6 ml/min, 
respectively, for inner and outer nozzle from the two syringe pumps produced a jet 
consisting of outer shell and inner core containing islet suspension. An applied 
modulation frequency to the PPF system generated an acoustic excitation which broke the 
jet into uniformly sized microdroplets which were immediately collected into a gelling 
solution (50 mM CaCl2, 1 mM BaCl2, and 0.05% (v/v) Tween 20 in dH2O, pH 7.2) under 
gentle stirring. The average microcapsule production time with PPF system was 5 min. 
After 5 min gelling time, the crosslinked alginate microcapsules containing islets were 
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washed with PBS and re-dispersed in RPMI-1640 with 10% FBS and 1% PS, and 
incubated at 37 with 5% CO2.  
 
3.2.2. In vitro islet evaluation after encapsulation  
 Each aliquot (1 mL) of alginate microcapsules containing islets was transferred to 
two different calibration grids and used for in vitro assessment with DTZ and SYTO-
green/EB staining. The procedures were the same as described in previous chapter. 
Optical microscope was used to identify DTZ-stained islets and fluorescence microscope 
was used to qualitatively assess viability of encapsulated islets.  
   
3.2.3. Statistical analysis 
 All data are expressed as mean ± standard deviation (SD). Data comparisons were 
performed by student t-test. Differences with p < 0.05 were considered statistically 
significant. 
 
3.3. Results and Discussion 
3.3.1. Characterization of alginate microcapsules 
 Alginate, which can be formed into micro-scale hydrogel, is one of the 
biomaterials that already has been used for numerous biomedical applications due to its 
favorable properties such as biocompatibility and fast gelation process [123]. This study 
employed modified PPF method to produce uniformly sized alginate hydrogels for rapid 
islet encapsulation. The dual coaxial nozzle and the acoustic excitation generated from 
the PPF system produced alginate microdroplets with a core/shell structure as illustrated 
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in Figure 4. The generated acoustic excitation can produce microdroplets with the rate of 
> 1,000 drops/sec which allows rapid production process with high throughput, therefore 
making PPF method favorable for islet encapsulation. The diameter of the alginate 
microdroplets can be determined by the flow rates of inner core solution and outer shell 
solution along with the molecular weight and the concentration of the feeding solution 
[131]. PPF method produced uniform alginate microcapsules with an average diameter of 
500 μm using the dual coaxial nozzle with the inner flow rate of 2.3 ml/min and outer 
flow rate of 4.6 ml/min (1:2 ratio). 500 μm size alginate microcapsules were chosen for 
this experiment to accommodate all sizes of isolated porcine islets which usually ranged 
from 50 to 250 μm. The semi-permeable barrier of the alginate microcapsule, which is 
illustrated in Figure 5(a), is designed to protect encapsulated islets from immune cells 
while letting islets survive and function for a prolonged period of time [132].  
 
3.3.2. In vitro islet evaluation after encapsulation  
 The morphology of encapsulated islets remained to be spherical and structurally 
intact which indicates that no severe physical damage was done during the encapsulation 
process. DTZ staining further confirmed that insulin-secreting beta cells were present in 
the islet clusters with rigid surface barrier as shown in Figure 5(b). The core of the 
alginate microcapsules, which consisted of relatively low alginate concentration (1.5%) 
and lower crosslinking density than the outer shell, had more flexible environment to 
safely secure the encapsulated islets. Additionally, the outer shell of the microcapsules 
with relatively high alginate concentration (2.0%) and crosslinking density prevented any 
islets from protruding from the microcapsules. Cell protrusion could lead to rejection 
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followed by necrosis and graft failure, therefore, it is very important to avoid it in order to 
achieve immunoisolation in microencapsulation [133, 134]. Figure 6 shows the optical 
and fluorescence micrographs of the alginate microcapsules containing islets where the 
SYTO-green and EB staining was used to visually and qualitatively assess the viability of 
encapsulated islets. There was no significant decrease in viability observed after the 
encapsulation due to fast encapsulation procedure with modified PPF method.  
 
3.4. Conclusion 
 The present method using PPF system demonstrated a fast production of uniform 
alginate microcapsules containing islets with control in microcapsule diameter. The islets 
showed no significant damage after the encapsulation which further supports the 
feasibility of using PPF method for future porcine islet xenotransplantation applications. 
Future in vivo study needs to be done to further demonstrate the immunoisolation 
capability of microencapsulation strategy using PPF system.  
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3.5. Figures 
 Figure 4. Schematic of PPF system for live cell encapsulation  
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  Figure 5. (a) A schematic of islet encapsulation with semi-permeable alginate microcapsules and (b) optical micrograph of islet encapsulated in alginate microcapsule after DTZ staining. Scale bar = 200 μm.   
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 Figure 6. Optical (left) and fluorescence (right) micrographs of encapsulated islets. SYTO-green staining and ethidium bromide (EB) staining were used to visualize islet viability after encapsulation. SYTO-green (green) stains viable islets and EB (red) stains dead islets.  Scale bar = 500 μm (top) and 200 μm (bottom).  
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CHAPTER 4 
CONCLUSION AND FUTURE WORK 
 
 Microencapsulation technology has been widely utilized in various fields of 
biotechnology, especially in the medical and pharmaceutical industry. In order to enhance 
the efficiency and efficacy of using microencapsulation in clinical trials, it is important to 
have control in the following key aspects: microcapsule size and uniformity control, 
permeability, prevention of cell protrusion, reproducibility, and throughput. Precision 
particle fabrication (PPF) system was previously used to produce micro-scale capsules 
with many synthetic and natural biomaterials such as PLGA, PCL, PEG-PCL copolymer, 
gelatin, chitosan and alginate for different biotechnology applications. Alginate, which 
has good biocompatibility and fast gelling mechanism, is still widely used in various 
biomedical applications, especially in the field of xenotransplantation of porcine islets. 
PPF system’s single step process using coaxial dual nozzle and acoustic excitation could 
easily handle highly viscous alginate solution to produce monodisperse microcapsules 
with core/shell structure and porosity. The size of the microcapsule can be controlled 
using different flow rates, frequency of the acoustic excitation, and alginate concentration. 
The PPF system also allows high throughput by producing alginate microcapsules at a 
rate of >1,000 drops/sec.  
 This study first reviewed and established the conventional method of isolating and 
purifying porcine islets using 5-6 month old commercial breed pigs provided by the 
University of Illinois slaughterhouse. Securing sufficient amount of isolated porcine islets 
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is the first crucial step towards islet xenotransplantation as it could solve the problem of 
donor shortage. 
 Furthermore, this study demonstrated the feasibility of using PPF method in 
microencapsulation of porcine islets for the treatment of type 1 diabetes. Monodisperse 
alginate microcapsules with a size of 500 μm were produced to encapsulate viable 
porcine islets which were isolated and purified the day before the encapsulation. The 
results showed viable and functioning porcine islets after the isolation and purification. 
The core/shell structure of the alginate microcapsules was designed to safely protect islets 
from host’s immune reactions, therefore achieving immunoisolation. Due to the fast and 
easy one step process of PPF system along with the fast gelation process of alginate, the 
porcine islets after the encapsulation still remained viable without any severe damage.  
 The future work will be to facilitate and monitor prolonged viability and function 
of encapsulated islets in vitro and in vivo. Additional future study will use PPF system to 
co-encapsulate islets and various active agents, with the capability to synergistically 
support islets, to observe improved survivability and function of encapsulated islets for 
prolonged period of time.  
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